Thursday, January, 17, 2019 02:56:25

Contribution By Ojaswita Kutepatil


AstraZeneca inks deal with Sobi to sell the US rights for Synagis®

AstraZeneca, the pharmaceutical firm headquartered in Cambridge, has confirmed the sale of the U.S. rights to Synagis®, which is used for preventing respiratory tract infections, to specialty biopharmaceutical company Sobi AB. The multibillion-dollar deal would also involve nearly 130 workers being transferred to the Swedish …